Please select the option that best describes you:
What would you recommend as first line therapy for metastatic chromophobe RCC?
Answer from: Medical Oncologist at Academic Institution
Albeit limited data, I favor an IO-TKI doublet for chromophobe RCC. The recent B61 trial with Len/Pembro showed a response rate in the 25% range for this historically IO non-responsive subtype. I think all patients should get an IO-based regimen up front as no other regimens have curative potential....
Sign In or Register to read more